Trial Profile

Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cancer vaccines (Primary) ; Poly ICLC (Primary)
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Transitional cell carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

18 Jun 2026 Protocol has been amended to include 2 new arms (Experimental: Cohort 3: Melanoma and Experimental: Cohort 4: Non-Small Cell Lung Cancer) , it has changed from 2 to 4.
18 Jun 2026 Planned number of patients changed from 16 to 64.
18 Jun 2026 Planned End Date changed from 31 Mar 2033 to 30 Jun 2034.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com